Tear interleukin-6 and clinical activity in thyroid eye disease
Biomolecules and Biomedicine · 08.10.2026
DOI: 10.17305/bb.2026.14860 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 08.10.2026. Verfasst von Nayeli Alcaraz-Lares und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orbit and Oculoplastic Surgery, Instituto de Oftalmologia "Fundacion Conde de Valenciana", IAP, Mexico City, Mexico. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Thyroid eye disease (TED) is an autoimmune orbital disorder in which interleukin-6 (IL-6) may reflect inflammatory activity. We evaluated tear IL-6 concentrations across disease activity groups, their association with the Clinical Activity Score (CAS), and paired tear–serum differences. This prospective cross-sectional study included 42 adults: 15 with active TED (CAS ≥3), 14 with inactive TED (CAS 0–2), and 13 healthy controls. IL-6 was measured in diluted tear samples collected by micro-volume wash and paired serum using cytometric bead array with flow cytometry. Analyses comprised one-way analysis of variance, paired Student t-tests, and Pearson correlation. Mean tear IL-6 concentrations were 22.33, 8.49, and 3.82 pg/mL in active TED, inactive TED, and controls, respectively, with a significant overall difference across groups (p = 0.002). Tear IL-6 concentrations exceeded serum concentrations in active and inactive TED (p = 0.001 and p = 0.005, respectively), with no significant difference in controls (p = 0.309). In active TED, tear IL-6 correlated positively with CAS (r = 0.55; 95% confidence interval, 0.05–0.83; p = 0.032). These exploratory findings support further investigation of tear IL-6 as a correlate of clinical activity. Unmeasured ocular-surface status, unquantified tear dilution, and extrapolation below the assay’s lowest calibrator limit interpretation; larger longitudinal studies incorporating objective ocular-surface assessment and assays validated for tear fluid are needed before clinical application.
Autor:innen und Institutionen
- Department of Orbit and Oculoplastic Surgery, Instituto de Oftalmologia "Fundacion Conde de Valenciana", IAP, Mexico City, Mexico.
Zitieren
APA
Alcaraz-Lares, N., Mejia-Llanes, D. B., & Nava-Castañeda, A. (2026). Tear interleukin-6 and clinical activity in thyroid eye disease. Biomolecules and Biomedicine. https://doi.org/10.17305/bb.2026.14860
Vancouver
Alcaraz-Lares N, Mejia-Llanes DB, Nava-Castañeda A. Tear interleukin-6 and clinical activity in thyroid eye disease. Biomolecules and Biomedicine. 2026. doi:10.17305/bb.2026.14860
BibTeX
@article{AlcarazLares2026,
author = {Alcaraz-Lares, Nayeli and Mejia-Llanes, Daniel B and Nava-Castañeda, Angel},
title = {Tear interleukin-6 and clinical activity in thyroid eye disease},
journal = {Biomolecules and Biomedicine},
year = {2026},
doi = {10.17305/bb.2026.14860}
}
EUVIMED